California Cancer Associates for Research and Excellence, better known locally as cCare, has been purchased by Integrated Oncology Network.

Founded in 1993, cCare provides comprehensive cancer treatment in Fresno and San Diego. The Fresno center is at  7130 N. Millbrook Ave., across Herndon Avenue from Saint Agnes Medical Center.

In addition, a publicly-traded company based in Cerritos, the Oncology Institute of Hope and Innovation, acquired Women’s Cancer Care in northeast Fresno in a transaction announced Monday. Until a rebranding last spring, Women’s Cancer Care had been known for 25 years as California Oncology of the Central Valley.

Purchase Makes ION One of Nation’s Largest Oncology Providers

ION’s acquisition of cCare, which was announced on April 22, creates one of the largest oncology providers in the United States, with 57 centers in 14 states.

Dr. Jedidiah Monson, a radiologist and the president of cCare, said in a news release that “our team is excited to partner with ION, whose highly complementary offerings, vision, and culture will facilitate a seamless integration.”

Said ION Chief Executive Officer Josh Johnson: “cCARE has established an outstanding reputation throughout Southern and Central California due to the strength and quality of its physician base and proven ability to deliver exceptional patient outcomes. We are thrilled to partner with the cCARE team. … ”

ION is owned by a private-equity firm, Silver Oak Services Partners, LLC, which is based in Evanston, Illinois.

“ION’s deep and highly experienced management team paired with Silver Oak’s additional capital and expertise will accelerate current and future growth initiatives across the combined platform,” Dr. Monson said.

‘Patients Will Benefit’ From TOI’s Cutting-Edge Care: Dr. Perkins

Women’s Cancer Care, which is at 6121 N. Thesta Ave., Suite 204, is the only clinic between San Francisco and Los Angeles specializing in breast and gynecology oncology patients. It is led by Dr. Christopher R. Perkins and Dr. Lisa Ge.

“The addition of Women’s Cancer Care offers a unique opportunity for TOI to not only expand our footprint into the Central Valley, but also provide care to a focused patient population that will benefit from our leading clinical research programs, care management resources, and more,” said Dr. Daniel Virnich, president of TOI.

Said Dr. Perkins: “Our patients will benefit greatly from the cutting-edge care solutions that TOI provides, and I look forward to growing this practice to serve even more patients.”

Shares in TOI, which is listed on NASDAQ, have risen since the purchase was announced. The stock was trading at $9.92 on Wednesday morning.